吉非替尼聯(lián)合吉西他濱和順鉑治療晚期非小細(xì)胞肺癌的療效

打開文本圖片集

摘 要 目的：觀察吉非替尼聯(lián)合吉西他濱和順鉑治療晚期非小細(xì)胞肺癌的臨床效果。方法：將98例晚期非小細(xì)胞肺癌患者隨機(jī)分成對照組和研究組，各49例。對照組實(shí)施吉西他濱聯(lián)合順鉑治療，研究組在對照組基礎(chǔ)上加用吉非替尼，對比兩組臨床療效。結(jié)果：治療后，研究組治療總有效率，CD3+、CD4+水平和CD4+/CD8+比值均高于對照組；CD8+水平和不良反應(yīng)發(fā)生率均低于對照組（P

關(guān)鍵詞 吉非替尼 吉西他濱 順鉑 晚期非小細(xì)胞肺癌 療效

中圖分類號：R979.19； R734.2 文獻(xiàn)標(biāo)志碼：A 文章編號：1006-1533（2023）07-0011-03

引用本文 陳輝， 黃武君， 崔明良. 吉非替尼聯(lián)合吉西他濱和順鉑治療晚期非小細(xì)胞肺癌的療效[J]. 上海醫(yī)藥， 2023， 44（7）： 11-13.

Efficacy of gefitinib combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer

CHEN Hui， HUANG Wujun， CUI Mingliang

（Department of Oncology， Balihu General Hospital， the First People’s Hospital of Jiujiang City， Jiujiang 332000， China）

ABSTRACT Objective： To observe the clinical effect of gefitinib combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer. Methods： Ninety-eight patients with advanced non-small cell lung cancer were randomly divided into a control group and a study group with 49 cases each. The control group was treated with gemcitabine combined with cisplatin， while the study group was treated with gefitinib besides gemcitabine combined with cisplatin. The clinical efficacy was compared between the two groups. Results： The overall clinical efficacy， the levels of CD3+， CD4+， and CD4+/CD8+ were higher， and the level of CD8+ and the incidence of adverse events were lower in the study group than the control group after the treatment （P

KEY WORDS gefitinib； gemcitabine； cisplatin； advanced non-small cell lung cancer； efficacy

肺癌是一種患病率、致死率較高的惡性腫瘤，其中非小細(xì)胞肺癌（non-small cell lung cancer， NSCLC）約占80%[1]。（剩余3404字）